The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Update on phase III pivotal trial of Bria-IMT + CPI vs physician’s choice in advanced metastatic breast cancer (BRIA-ABC).
 
Saranya Chumsri
Honoraria - Roche Thailand
Consulting or Advisory Role - AstraZeneca/Daiichi Sankyo; Athenex; Athenex; Axiom Healthcare Strategies; bioTheranostics; bioTheranostics (Inst); Cardinal Health; Cepton Strategies; Daiichi Sankyo/Astra Zeneca; Eisai; Equinox Group; Eradigm Consulting; Genentech; Gilead Sciences; Immunomedics; Immunomedics; Immunomedics; MDoutlook; Novartis; Novartis; Novartis (Inst); Puma Biotechnology; Seagen; Syndax
Research Funding - Array BioPharma; Briacell (Inst); Merck; Salix
 
Joyce O'Shaughnessy
Honoraria - AADi; Agendia; Amgen; Aptitude Health; AstraZeneca; BioNTech; Bristol-Myers Squibb; Daiichi Sankyo; DAVA Oncology; DualityBio; Eisai; Ellipses Pharma; Exact Sciences; G1 Therapeutics; Genentech; Gilead Sciences; Guardant Health; HiberCell; Jazz Pharmaceuticals; Johnson & Johnson; Lilly; Menarini Group; Merck; Mersana; Natera; Novartis; Pfizer; Pierre Fabre; Puma Biotechnology; Roche; Sanofi; Seagen; Stemline Therapeutics; Summit Therapeutics; Tempus; Tersera
Consulting or Advisory Role - AADi; Agendia; Amgen; Aptitude Health; AstraZeneca; BioNTech; Bristol-Myers Squibb; Daiichi Sankyo; DAVA Oncology; DualityBio; Eisai; Ellipses Pharma; Exact Sciences; G1 Therapeutics; Genentech; Gilead Sciences; Guardant Health; HiberCell; Jazz Pharmaceuticals; Johnson & Johnson; Lilly; Menarini Group; Merck; Mersana; Natera; Novartis; Pfizer; Pierre Fabre; Puma Biotechnology; Roche; Sanofi; Seagen; Stemline Therapeutics; Summit Therapeutics; Tempus; Tersera
Travel, Accommodations, Expenses - Aptitude Health; Daiichi Sankyo; DAVA Oncology; Lilly; Merck; Novartis; Roche
 
Azka Ali
Honoraria - Tersera
Consulting or Advisory Role - AstraZeneca; Gilead Sciences; Guardant Health; Guardant Health
Research Funding - AstraZeneca/Daiichi Sankyo (Inst); Symbiosys
Travel, Accommodations, Expenses - Tersera
 
Christopher Vaughn
Research Funding - Briacell
 
Kristine Rinn
Research Funding - Briacell
 
Adam Brufsky
Consulting or Advisory Role - Agendia; Daiichi Sankyo/Lilly; Eisai; Genentech/Roche; General Electric; Gilead Sciences; Lilly; Merck; Myriad Pharmaceuticals; Novartis; Pfizer; Puma Biotechnology
Research Funding - AstraZeneca/Daiichi Sankyo (Inst); Gilead Sciences (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst); Puma Biotechnology (Inst); Roche/Genentech (Inst)
Expert Testimony - Pfizer; Sanofi
 
Lawrence Negret
Research Funding - Briacell
 
Regina Stein
Research Funding - Briacell
 
Blaise Bayer
Employment - Briacell
 
Marcela Salgado
Employment - Briacell
 
Giuseppe Del Priore
Employment - Briacell
Leadership - Briacell
Stock and Other Ownership Interests - Briacell
 
Sara Hurvitz
Stock and Other Ownership Interests - ROM Tech (I)
Research Funding - Ambryx (Inst); Amgen (Inst); Arvinas (Inst); AstraZeneca/Daiichi Sankyo (Inst); Bayer (Inst); Biomarin (Inst); Cascadian Therapeutics (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Dantari (Inst); Dignitana (Inst); G1 Therapeutics (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Greenwich LifeSciences (Inst); Immunomedics (Inst); Lilly (Inst); Loxo/Lilly (Inst); Macrogenics (Inst); Merrimack (Inst); Novartis (Inst); Orinove (Inst); Orum (Inst); Pfizer (Inst); Phoenix Molecular Designs (Inst); Pieris Pharmaceuticals (Inst); Puma Biotechnology (Inst); Radius Health (Inst); Samumed (Inst); sanofi (Inst); Seagen (Inst); Stemline/Menarini (Inst); Zymeworks (Inst)
Other Relationship - BeiGene (Inst); BMS (Inst); Boehringer Ingelheim; Briacell (Inst); BridgeBio Pharma (Inst); Celcuity; Embiosys; Gilead Sciences (Inst); InClin/Atossa; Jazz Pharmaceuticals (Inst); Luminate (Inst); Medsir; Mersana (Inst); Novartis; Pfizer; Roche; Roche (Inst)